Skip to main content

Corporatism and Big Pharma

Buy Article:

$24.00 plus tax (Refund Policy)

The pharmaceutical industry has leveraged public policy to its benefit, prohibiting the federal government from discounts on drug prices through bulk purchases while using the tax code to develop Patient Assistance Foundations to claim charitable contributions as well as justifying moving income overseas to reduce tax liability. Consumers and taxpayers are left covering the costs of Big Pharma's corporatism. Regulatory reforms are proposed to make drug companies more socially responsible.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: CORPORATISM; PHARMACEUTICAL INDUSTRY; REGULATORY REFORMS

Document Type: Research Article

Publication date: 2016-04-01

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more